Advancements in the Management of R/R AML: ASH 2024 - Episode 2

Treatment Goals and Unmet Needs in R/R AML

January 3, 2025

Thomas W. LeBlanc, MD, MA, MHS, FAAHPM, FASCO , James Blachly, MD, Aaron Goldberg, MD, PhD Memorial Sloan Kettering Cancer Center, Rami Komrokji, MD, Gabe Mannis, MD , Michael J. Thirman, MD

Panelists discuss how achieving responses with second-line treatment options after venetoclax-based regimens remains challenging, and explore strategies for bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients who relapse post venetoclax while also addressing the evolving management of patients following transplant.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Treatment Strategies for Relapsed/Refractory AML Patients

Now Viewing

EP. 2: Treatment Goals and Unmet Needs in R/R AML

EP. 3: Navigating Challenges in Second- and Third-Line AML Therapy

EP. 4: Revumenib’s FDA Approval and Clinical Implications

EP. 5: Efficacy and Potential of Revumenib in KMT2A-Translocated Leukemia

EP. 6: Adverse Event Management and Patient Safety With Revumenib

EP. 7: MRD Testing and the Role of Revumenib in Treatment Response

EP. 8: Integrating Revumenib Into Current R/R AML Treatment Paradigms

EP. 9: Genetic Testing and Molecular Profiling in AML

EP. 10: Emerging Combination Strategies and Preclinical Findings

EP. 11: Future Perspectives on Menin Inhibitors in Acute Leukemias

EP. 12: Closing Perspectives on R/R AML Treatment Advances

Video content above is prompted by the following:

Briefly comment on your clinical experience with the difficulty achieving responses with the currently available second line and beyond treatment options after patients are treated with venetoclax plus azacitidine (or decitabine).
How do current therapies meet the needs of patients post-venetoclax failure?
How often are you able to bring your patients to allo-HSCT once they relapse post venetoclax? How are utilizing the currently available R/R options as bridging therapy to allo-HSCT?
How are you managing patients following a transplant? Do you see this changing in the future?